Cellipont Bioservices and Xiogenix Publish Fill-Finish White Paper for Scalable Cell Therapy Manufacturing

Downstream formulation and fill-finish remain a persistent bottleneck as cell therapy programs advance from clinical to commercial scale, and Cellipont Bioservices has now published quantified performance data to address it. The CDMO, in collaboration with Xiogenix, released a white paper evaluating the ARES™ X20+ automated fill-finish platform across small and large-scale cell therapy manufacturing workflows.

The evaluation documented consistent formulation performance across an approximately 17-fold increase in process scale. Final formulation volume accuracy measured 98.2% at small scale and 103.6% at large scale, with cell viability remaining stable before and after automated formulation, a result that directly bears on batch release decisions and comparability assessments under ICH Q10 quality system expectations.

For QA directors and process validation leads, the contamination risk dimension carries particular weight. Manual and semi-automated fill-finish steps introduce handling variability that complicates sterility assurance and reproducibility documentation under 21 CFR Part 211. The white paper frames automation as a mechanism for reducing those variables while preserving flexibility across different batch sizes and container formats, a combination that matters when clinical-stage processes must translate to commercial GMP environments without revalidation from scratch.

The evaluation also generated practical engineering feedback that informed next-generation enhancements to the ARES™ X20+ platform, including improvements to priming, single-use kit capacity, pressure integrity monitoring, gravimetric control, pump calibration, and product recovery. That iterative loop between CDMO operational experience and equipment development is increasingly relevant as sponsors seek platform technologies that can absorb process changes without triggering major validation cycles.

Cellipont will be present at the 11th CAR-TCR Summit, September 15–17, 2026, in Boston, where automated manufacturing scalability is among the agenda topics; the full white paper is available via the company's website.

Source: Cellipont Bioservices via Cision, September 9, 2026.